NCT05747157 2023-11-21
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research
Anhui Provincial Hospital
Phase EARLY_PHASE1 Unknown
Clinical Trials
11 trialsNCT05105867 2023-05-10
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1 Unknown
NCT05651191 2022-12-14
To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05480501 2022-07-29
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04626726 2020-11-13
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04129099 2020-05-28
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Hebei Yanda Ludaopei Hospital
Phase EARLY_PHASE1 Unknown
NCT04264039 2020-02-11
Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT04191941 2019-12-10
Treatment of Hematological Malignancy With Novel CAR-T Cells.
Timmune Biotech Inc.
Phase EARLY_PHASE1 Unknown
NCT04184414 2019-12-03
The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04166838 2019-11-18
The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)
Shanghai Longyao Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03825731 2019-01-31
A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Hebei Yanda Ludaopei Hospital
Phase EARLY_PHASE1 Unknown